USP9X and chronic myelogenous leukemia, BCR-ABL1 positive: The USP9X inhibitor WP1130 lowers MCL-1 levels in chronic myelogenous leukemia and enhances sensitivity to apoptosis by facilitating MCL-1 degradation [29].